Sipavibart reduced symptomatic COVID-19 by 34.9% compared to standard treatment, but efficacy was only observed against non–Phe456Leu-containing variants, according to new phase 3 trial data.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
In a new study on the long-term health risks post–COVID-19 hospitalization, researchers reported an "increased risk of death or hospitalization for various organ disorders up to 30 months after discharge."
Americans report record-low mental and physical health assessments in Gallup survey, with young women experiencing steepest mental health decline since the COVID-19 pandemic began despite end of public health emergency.